سعر سورال 20مجم 3 فيال 2024

Tenoxicam 20 mg vials for intramuscular or intravenous injection, pack of 3 vials; Global Napi Pharmaceuticals, Egypt.

• Symptomatic treatment of painful inflammatory and degenerative musculoskeletal disorders in adults: rheumatoid arthritis, osteoarthritis, arthrosis, ankylosing spondylitis, and extra-articular disorders (tendinitis, bursitis, periarthritis, strains and sprains).Population: AdultsMedsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Post-operative pain.Population: AdultsMedsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Common: dizziness, headache, gastric/epigastric/abdominal pain, dyspepsia, nausea. Uncommon: GI bleeding and ulcer, constipation, diarrhoea, vomiting, mouth ulceration, raised liver enzymes, pruritus, rash, urticaria, raised urea or creatinine. Very rare: Stevens-Johnson syndrome, toxic epidermal necrolysis, pancreatitis.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Hypersensitivity to tenoxicam, the excipients or other NSAIDs, or previous asthma, rhinitis, angioedema or urticaria caused by salicylates or other NSAIDs.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Active or previous NSAID-related gastrointestinal bleeding or perforation, or active or recurrent peptic ulcer or haemorrhage; haemorrhagic diathesis.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Severe heart failure, renal failure or hepatic failure; third trimester of pregnancy.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Use the lowest effective dose for the shortest duration; avoid combination with other NSAIDs including COX-2 inhibitors; take care when plasma albumin is markedly reduced (high protein binding).International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• NSAIDs may be associated with a small increased risk of arterial thrombotic events and can cause fluid retention, oedema and new or worsened hypertension; use only after careful consideration in uncontrolled hypertension, heart failure, ischaemic heart, peripheral arterial or cerebrovascular disease.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Gastrointestinal bleeding, ulceration or perforation, which can be fatal, may occur at any time; risk is higher in the elderly; consider protective agents (misoprostol or a proton pump inhibitor) in at-risk patients.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Salicylates and other NSAIDsSalicylates increase tenoxicam clearance and displace it from protein binding; concomitant NSAIDs increase the risk of adverse reactions and should be avoided.Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Anti-platelet agents, SSRIs, corticosteroids and anticoagulantsIncreased risk of gastrointestinal bleeding; careful monitoring is advised with anticoagulants.Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• MethotrexateSome NSAIDs reduce renal tubular secretion of methotrexate, raising its levels and toxicity.Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Should not be used in the first two trimesters unless the expected benefit outweighs the fetal risk; prostaglandin synthesis inhibitors in early pregnancy are associated with increased risk of miscarriage and cardiac malformation; use in the second or third trimester may cause fetal renal dysfunction and oligohydramnios.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• A very small amount (mean under 0.3% of the dose) passes into breast milk; no adverse effects in breastfed infants are known, but the data sheet advises weaning or stopping the medicine.International label, equivalent formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Tenoxicam: Inhibits cyclooxygenase and thereby peripheral prostaglandin synthesis, giving anti-inflammatory and analgesic effects.